drugset / Trial / NCT06279130
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
Timeline
- Start
- 2024-01-29
- Primary completion
- 2029-01-29
- Completion
- 2034-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Balstilimab | Monoclonal antibody | 450 mg | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | 25 mg | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Docetaxel | Small molecule | 50 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |
Indications
No indication recorded.